## Australian-wide Survey of Lung Cancer Care -

Start of Block: Intro

Q1 We would be grateful please for less than 5 minutes of your time to complete this survey which is designed to provide a snapshot of the current status of lung cancer care and MDTs around Australia.

- These data will help inform vital services planning for lung cancer care and will directly inform ongoing discussions with Government about lung cancer care across Australia.
- We are only asking for <u>one response from each institution</u>, we suggest it is the lead clinician for the lung cancer MDT.
- Participation is voluntary. You have the right to withdraw from the study at any point without penalty. Apart from giving up your time, we do not expect that there will be any risks or inconveniences associated with taking part in this study.
- Curtin University Human Research Ethics Committee (HREC) has approved this study (HREC number HRE\_\_\_\_\_). Should you wish to discuss the study with someone not directly involved, in particular, any matters concerning the conduct of the study or your rights as a participant, or you wish to make a confidential complaint, you may contact the Ethics Officer on (08) 9266 9223 or the Manager, Research Integrity on (08) 9266 7093 or email hrec@curtin.edu.au.
- The name of your institution is needed to avoid duplicates. We will *not* use the name of your institution in any data summaries or reports. Data will be held at Curtin University and an anonymised summary report passed to Lung Foundation Australia, and other interested parties. Thank you for your time.

Investigator team: Chief Investigator: Co-investigator:
O By checking this box, you consent to proceeding with this survey and agree to have the data you provide stored and analysed as described above.
End of Block: Intro
Start of Block: Regarding your place of work where you care for lung cancer patients

Page 1 of 13

Q2 Regarding your place of work where you care for lung cancer patients: Please provide the name of your institution (essential to avoid duplicates)
Q3 Please confirm if your institution where you care for lung cancer patients is public or private.
O Public (1)
O Private (2)
Q4 In which State or Territory is your institution based?
O ACT (1)
O NSW (2)
O NT (3)
O QLD (4)
O SA (5)
O TAS (6)
○ VIC (7)
○ WA (8)

Q5 Where is your institution located?
O Rural (1)
O Regional (2)
O Metro (3)
End of Block: Regarding your place of work where you care for lung cancer patients
Start of Block: More detail about your lung cancer service
Q6 Approximately how many new lung cancer cases does your institution see a year?
O-49 (1)
O 50-99 (2)
O 100-199 (3)
○ >200 (4)
Q7 More detail about your lung cancer services:
Does your institution have a regular lung cancer MDT?
○ Yes (1)
O No (2)
Display This Question:
If More detail about your lung cancer services: Does your institution have a regular lung cancer MDT? = Yes

Page 3 of 13

Q8 How often is your MDT?
○ Weekly (1)
O Every 2 weeks (2)
O Monthly (3)
Other (4)
Display This Question:  If More detail about your lung cancer services: Does your institution have a regular lung cancer  MDT? = Yes
Q9 What IT / software program does your MDT use? (Select all that apply)
None (1)
Excel (2)
Access (3)
RedCap (4)
Own database (5)
Commercial program (please name) (6)
Display This Question:  If More detail about your lung cancer services: Does your institution have a regular lung cancer  MDT? = Yes

Page 4 of 13

Q24 Who performs data entry of clinical information during / from the MDT (tick all that apply)
Clinicians - Consultant, Fellow, Registrars (1)
Nurse specialist (2)
MDT coordinator / admin support (3)
Other (4)
Display This Ougstion:
Display This Question:  If More detail about your lung cancer services: Does your institution have a regular lung cancer MDT? = Yes
Q10 Please provide additional comments about the IT support for your MDT / links to electronic patient records.
<del></del>
- <del></del>
<del></del>
Display This Question:  If More detail about your lung cancer services: Does your institution have a regular lung cancer  MDT? = Yes
Q22 Does your MDT perform a regular audit of practice against local / national guidelines?
○ Yes, regularly (1)
○ Yes, ad hoc (2)
Overy infrequently (3)
O No (4)

Display This Question:
If More detail about your lung cancer services: Does your institution have a regular lung cancer MDT? = Yes
WDT? - Yes
Q23 Does your MDT perform regular quality control of data entry?
○ Yes, regualrly (1)
○ Yes, ad hoc (2)
O Very infrequently (3)
○ No (4)
Display This Question:
If More detail about your lung cancer services: Does your institution have a regular lung cancer
MDT? = Yes
Q25 Does your MDT act as a means for recruitment to clinical trials
○ Yes - frequently (1)
O Yes - ad hoc, infrequent (2)
O No - no formal or regular process for this (3)
Other comment (4)
End of Block: More detail about your lung cancer service
Start of Block: Your lung cancer team and resources
Q11 Your lung cancer team and resources: Does your institution have a dedicated specialist lung cancer nurse?
O No (1)
O Yes - please state full time equivalent / number of sessions a week (2)
<del></del>

Page 6 of 13

Q12 Who <u>regularly</u> attends your lung cancer MDT? (tick all that apply)
Respiratory physician (1)
Medical oncology (2)
Radiation oncology (3)
Radiology (4)
Nuclear medicine (5)
Histopathology (6)
Lung cancer specialist nurse (7)
Palliative care consultant (8)
Palliative care nurse (9)
Thoracic surgeon (10)
MDT admin / coordinator (11)
Trainee doctors (12)
Clinical psychologist (13)
Clinical trials coordinator (14)
Dietician (15)
Pharmacist (16)
Physiotherapist (17)
Social Worker (18)

Page 7 of 13

apply.)  EBUS bronchoscopy (1)	
Thoracic surgery (2)	
Medical oncology (3)	
Radiation oncology - XBRT (4)	
Radiation oncology - SABR (7)	
Palliative care (8)	
PET-CT (9)	
Q14 Do you have any other comments about lung cancer services in your institution?	
End of Block: Your lung cancer team and resources	
End of Block: Your lung cancer team and resources  Start of Block: Block 5	

Discussions are on-going with the Federal Government regarding the establishment of a national lung cancer registry.

This would be designed to provide national data on lung cancer care and to use such data to drive changes in clinical quality, where needed.

Page 8 of 13

On a sca quality reg	ale from 0-10, how supportive are you of such a proposed national lung cancer clinical gistry?
O 0	(0)
O 1	(1)
O 2	(2)
Оз	(3)
<b>O</b> 4	(4)
O 5	(5)
O 6	(6)
O 7	(7)
0 8	(8)
O 9	(9)
O 10	(10)

	_	_	
(	7	2	1

Please tell us how urgent a need you think there is for a concerted national approach to improving lung cancer care and services in Australia.

- 0 (0)
- 0 1 (1)
- O 2 (2)
- O<sub>3</sub> (3)
- 0 4 (4)
- O 5 (5)
- O 6 (6)
- 0 7 (7)
- 0 8 (8)
- 0 9 (9)
- 0 10 (10)

**End of Block: Block 5** 

Start of Block: Lastly - impact of COVID-19

Q15 Lastly - impact of COVID-19:	
Please advise how COVID-19 has impacted the lung cancer patient care in your institution?	
O 0 (0)	
O 1 (1)	
O 2 (2)	
O <sub>3</sub> (3)	
O 4 (4)	
O 5 (5)	
O 6 (6)	
O 7 (7)	
O 8 (8)	
O 9 (9)	
O 10 (10)	
Q16 Please comment on the above if appropriate	

217 Please advise now COVID-19 has impacted on the running of your MD1.
None - no impact (1)
Minimal impact or change (2)
Meeting now entirely online (Teams / Zoom etc.) (3)
Meeting now hybrid (face to face and online) (4)
Other comments / innovations / changes: (5)
Moderate impact / changes (6)
Severe impact / changes (7)
Page Break ————————————————————————————————————

Q18 Thank you for your contribution to helping us inform vital services planning for lung cancer care and ongoing discussions with Government about lung cancer services across Australia.

We would like to contact you regarding the results of this survey and of future work towards more harmonised lung cancer services.

Please provide your email address if you are willing to be contacted.